PMID- 15601744
OWN - NLM
STAT- MEDLINE
DCOM- 20050628
LR  - 20151119
IS  - 1046-6673 (Print)
IS  - 1046-6673 (Linking)
VI  - 16
IP  - 2
DP  - 2005 Feb
TI  - Urine chemokines as biomarkers of human systemic lupus erythematosus activity.
PG  - 467-73
AB  - The purpose of this study was to evaluate urine monocyte chemoattractant 
      protein-1 (MCP-1) and IL-8 as biomarkers of SLE flare. Urine was collected every 
      2 mo from patients who were followed prospectively in the Ohio SLE Study. Renal 
      and nonrenal flares were identified and MCP-1 and IL-8 were measured by specific 
      ELISA in samples that were collected at flare. When available, MCP-1 and IL-8 
      were also measured in urine samples before and after flare. For comparison, MCP-1 
      and IL-8 were measured in the urine of healthy individuals and in renal and 
      nonrenal SLE patients with stable disease activity (disease controls). Most 
      patients were receiving maintenance immunosuppressive therapy before flare. At 
      renal flare, mean urine MCP-1 (uMCP-1) was significantly greater than uMCP-1 at 
      nonrenal flare and from healthy volunteers and renal disease controls. The level 
      of uMCP-1 correlated with the increase in proteinuria at flare and was higher in 
      patients with proliferative glomerulonephritis and in patients with impaired 
      renal function. Urine MCP-1 was increased beginning 2 to 4 mo before flare. 
      Patients who responded to therapy showed a slow decline in uMCP-1 over several 
      months, whereas nonresponders had persistently high uMCP-1. In contrast, uIL-8 
      did not change with disease activity and was not elevated at renal or nonrenal 
      flare compared with disease controls. In conclusion, uMCP-1 but not uIL-8 is a 
      sensitive and specific biomarker of renal SLE flare and its severity, even in 
      patients who receive significant immunosuppressive therapy. Persistently elevated 
      uMCP-1 after treatment may indicate ongoing kidney injury that may adversely 
      affect renal prognosis.
FAU - Rovin, Brad H
AU  - Rovin BH
AD  - Ohio State University, Nephrology Division, N210 Means Hall, 1654 Upham Drive, 
      Columbus, OH 43210, USA. rovin-1@medctr.osu.edu
FAU - Song, Huijuan
AU  - Song H
FAU - Birmingham, Dan J
AU  - Birmingham DJ
FAU - Hebert, Lee A
AU  - Hebert LA
FAU - Yu, Chack Yung
AU  - Yu CY
FAU - Nagaraja, Haikady N
AU  - Nagaraja HN
LA  - eng
GR  - M01 RR 00034/RR/NCRR NIH HHS/United States
GR  - P01 DK 55546/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20041215
PL  - United States
TA  - J Am Soc Nephrol
JT  - Journal of the American Society of Nephrology : JASN
JID - 9013836
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokines)
RN  - 0 (Interleukin-8)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Biomarkers/urine
MH  - Case-Control Studies
MH  - Chemokine CCL2/metabolism/*urine
MH  - Chemokines/metabolism/*urine
MH  - Cohort Studies
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Interleukin-8/metabolism/*urine
MH  - Lupus Erythematosus, Systemic/*diagnosis/*urine
MH  - Male
MH  - Middle Aged
MH  - Probability
MH  - Prognosis
MH  - Reference Values
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Urinalysis
EDAT- 2004/12/17 09:00
MHDA- 2005/06/29 09:00
CRDT- 2004/12/17 09:00
PHST- 2004/12/17 09:00 [pubmed]
PHST- 2005/06/29 09:00 [medline]
PHST- 2004/12/17 09:00 [entrez]
AID - ASN.2004080658 [pii]
AID - 10.1681/ASN.2004080658 [doi]
PST - ppublish
SO  - J Am Soc Nephrol. 2005 Feb;16(2):467-73. doi: 10.1681/ASN.2004080658. Epub 2004 
      Dec 15.